REG - IXICO plc - Directorate Change

IXICOAnnouncement

12/01/2024 09:45

For best results when printing this announcement, please click on link below:
http://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20240112:nRSL4564Za&default-theme=true

RNS Number : 4564Z  IXICO plc  12 January 2024

12 January 2024

 

 

IXICO plc

 

("IXICO" or the "Company")

 

CEO Succession

 

IXICO plc, (AIM: IXI), the medical imaging advanced analytics company
delivering insights in neuroscience, announces that Giulio Cerroni has
informed the Board of his intention to retire from his role as Chief Executive
Officer ("CEO") and director of the Company by the end of 2024 in accordance
with his notice period and to ensure a smooth handover of responsibilities.
The Board has begun the process to appoint a new CEO in line with its
succession plan and will update the market in due course.

 

For further information please contact:

 

 IXICO plc                                                                                +44 (0) 20 3763 7499
 Giulio Cerroni, Chief Executive Officer

 Grant Nash, Chief Financial Officer

 Cavendish Capital Markets Limited (Nominated Adviser and Sole Broker)                    +44 (0) 20 7220 0500
 Giles Balleny / Dan Hodkinson (Corporate Finance)

 Michael F Johnson / Tamar Cranford Smith (Sales)

 

This announcement contains inside information as stipulated under the retained
EU law version of the Market Abuse Regulation (EU) No. 596/2014 (the "UK MAR")
which is part of UK law by virtue of the European Union (Withdrawal) Act 2018.
The information is disclosed in accordance with the Company's obligations
under Article 17 of the UK MAR.

 

About IXICO

IXICO is dedicated to delivering insights in neuroscience to help transform
the advancement of investigational therapies for neurological diseases, such
as Huntington's disease, Parkinson's disease and Alzheimer's disease. The
Company's purpose is to advance medicine and human health by turning data into
clinically meaningful information, providing valuable new insights in
neuroscience by supporting pharmaceutical companies across all phases of CNS
clinical research. IXICO's goal is to be a leading advocate of artificial
intelligence in medical image analysis.

 

IXICO has developed and deployed breakthrough data analytics, at scale,
through its remote access technology platform, to improve the return on
investment in drug development and reduce risk and uncertainty in clinical
trials for the Company's pharmaceutical clients.

 

More information is available on www.IXICO.com (http://www.ixico.com/)  and
follow us on Twitter @IXICOnews

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  BOADZGMMNMZGDZM